TIM-3 as a new therapeutic target in systemic lupus erythematosus |
| |
Authors: | Hai-Feng Pan Ning Zhang Wen-Xian Li Jin-Hui Tao Dong-Qing Ye |
| |
Institution: | (1) Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, 230032 Hefei, Anhui, People’s Republic of China;(2) Department of Rheumatology, Anhui Provincial Hospital, 17 Lujiang Road, 230001 Hefei, Anhui, People’s Republic of China |
| |
Abstract: | T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) was the first surface molecule that specifically identifies
Th1 cells in both mice and human. Recently, identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3–Galectin-9
pathway as an important regulator of Th1 immunity and tolerance induction. Many previous studies have demonstrated that TIM-3
influences chronic autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. In addition, association of TIM-3
polymorphisms with susceptibility to several autoimmune diseases has been identified. Recent work has explored the role of
TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment
of SLE. In this review, we will discuss the TIM-3 pathway and the therapeutic potential of modulating the pathway in SLE. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|